

**Official Use Only - Security-Related Information**

NRC FORM 374

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 1 OF 4 PAGES  
Amendment No. 104  
Corrected Copy

**MATERIALS LICENSE**

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee  1. Borgess Medical Center		In accordance with letter dated May 9, 2016,	4. Expiration Date: November 30, 2022
2. 1521 Gull Road Kalamazoo, MI 49048		3. License number: 21-12275-02 is amended in its entirety to read as follows:	5. Docket No.: 030-02115 Reference No.: 030-35603/030-17349
6. Byproduct, source, and/or special nuclear material  A. Any byproduct material permitted by 10 CFR 35.100  B. Any byproduct material permitted by 10 CFR 35.200  C. Any byproduct material permitted by 10 CFR 35.300  D. Iodine-125	7. Chemical and/or physical form  A. Any  B. Any  C. Any  D. Sealed Sources (ISO Aid LLC, Model 1A1-125A (Advantage I-125); Medi-Physics, Model 6711 (OncoSeed))	8. Maximum amount that licensee may possess at any one time under this license  A. As Needed  B. As Needed  C. 1000 millicuries total  D. 350 millicuries total	9. Authorized use  A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100  B. Any imaging and localization study permitted by 10 CFR 35.200  C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.  D. Any manual brachytherapy procedure permitted by 10 CFR 35.400.

**Official Use Only - Security-Related Information**

**Official Use Only - Security-Related Information**

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 2 OF 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

21-12275-02

Amendment No. 104

(Corrected Copy)

Docket or Reference Number

030-02115

030-35603/030-17349

**CONDITIONS**

10. A. Licensed material in Subitem Nos. 6.A. through 6.D. (excluding PET materials) shall be used at the licensee's facilities located at 1521 Gull Road, Kalamazoo, Michigan.
- B. Licensed material in Subitem Nos. 6.A and 6.B. (excluding PET materials) may be used or stored at the licensee's facilities located at Borgess - Heart Center for Excellence, 1722 Shaffer Street, Suite 1, Kalamazoo, Michigan; Borgess - Lee Memorial Hospital, 420 West High Street, Dowagiac, Michigan; and 3035 Capital Avenue, SW, Battle Creek, Michigan.
11. The Radiation Safety Officer (RSO) for this license is Paul Jursinic, Ph.D.
12. Licensed material shall only be used by, or under the supervision of:
- A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.
- B. The following individuals are authorized users for the material and medical uses as indicated:
- | <u>Authorized User(M.D.,D.O.,etc.)</u> | <u>Material and Use</u>           |
|--|-----------------------------------|
| Alicia Williams, M.D.                  | 10 CFR 35.200.                    |
| Brandon Tominna, M.D.                  | 10 CFR 35.200 and 35.300.         |
| Tammam Nehme, M.D.                     | 10 CFR 35.100 and 35.200.         |
| William LaPenna, M.D.                  | 10 CFR 35.100 and 35.200.         |
| John Gustafson, M.D.                   | 10 CFR 35.100 and 35.200.         |
| Srinivasan Dhatreecharan, M.D.         | 10 CFR 35.100 and 35.200.         |
| Nora Dajani, M.D.                      | 10 CFR 35.100 and 35.200.         |
| Marcio Curvelo, M.D.                   | 10 CFR 35.100 and 35.200.         |
| Stephen Brown, M.D.                    | 10 CFR 35.100, 35.200 and 35.300. |

**Official Use Only - Security-Related Information**

**Official Use Only - Security-Related Information**

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 3 OF 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number  
21-12275-02

Amendment No. 104  
(Corrected Copy)

Docket or Reference Number  
030-02115      030-35603/030-17349

Authorized User(M.D.,D.O.,etc.)

Daniel Bozarth, M.D.

Mark Shaman, M.D.

Linda Grossheim, M.D.

Anthony King, M.D.

Robert J. LaPenna, M.D.

Stephen L. Peck, M.D.

Gregorio U. Tan, M.D.

William B. Campbell, M.D.

Michael J. Todd, M.D.

Daniel C. Schroyer, M.D.

Craig Phillip Greenberg, M.D.

Shweta Aggarwal, M.D.

Arvind R. Patel, M.D.

Material and Use

10 CFR 35.100, 35.200 and 35.300.

10 CFR 35.100, 35.200 and 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries).

10 CFR 35.300 (limited to strontium-89 and samarium-153) and 35.400.

10 CFR 35.200.

10 CFR 35.200.

10 CFR 35.200.

10 CFR 35.200.

10 CFR 35.200.

10 CFR 35.100 and 35.200.

10 CFR 35.300 and 35.400.

10 CFR 35.300 (limited to oral administration of sodium iodide I-131 in quantities less than or equal to 33 millicuries)

10 CFR 35.200.

10 CFR 35.100 and 35.200.

13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.

**Official Use Only - Security-Related Information**

**Official Use Only - Security-Related Information**

NRC FORM 374A

U.S. NUCLEAR REGULATORY COMMISSION

PAGE 4 OF 4 PAGES

**MATERIALS LICENSE  
SUPPLEMENTARY SHEET**

License Number

21-12275-02

Amendment No. 104

(Corrected Copy)

Docket or Reference Number

030-02115

030-35603/030-17349

- A. Application dated September 30, 2010 (ML102810169)
- B. Letter dated July 20, 2009 (ML092080303)
- C. Letter dated September 15, 2010 (ML102810169)
- D. Letter dated March 31, 2011 (ML112150177)
- E. Letter dated May 17, 2011 (ML112620027)
- F. Letter dated April 29, 2011 (ML12205A233)
- G. Letters dated September 16, 2011 (ML112650039 and ML112650035)
- H. Letters dated April 27, 2012 (ML12173A142, ML12121A678 and ML12205A234)
- I. Letter dated July 9, 2012 (ML12200A394)
- J. Letter dated October 9, 2012 (ML12289A912)
- K. Letter dated October 12, 2012 (ML12289A918)
- L. Letter dated January 21, 2014 (ML14064A530)
- M. Letter dated August 25, 2014 (ML14240A614)



FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date: November 21, 2016

By: \_\_\_\_\_

*Colleen Carol Casey*  
Colleen Casey  
Region 3

**Official Use Only - Security-Related Information**